PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

Hinds, Pamela S.; Wang, Jichuan; Cheng, Yao I.; Stern, Emily; Waldron, Mia K.; Gross, Heather E.; DeWalt, Darren A.; Jacobs, Shana

doi:10.1002/pbc.27606

Cited by 56 publications

(64 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined with previous literature, this study offers strong evidence for the construct validity and responsiveness of PROMIS Pediatric measures in children and adolescents with cancer . We believe there is sufficient evidence for use of the PROMIS Pediatric measures in clinical trials, where there are few existing PRO measures that have been as extensively evaluated as PROMIS Pediatric measures .…”

Section: Discussionsupporting

confidence: 55%

“…They observed that the PROMIS Pediatric measures of depressive symptoms, fatigue, pain interference, and mobility correlated with similar items from the Symptom Distress Scale, providing support for PROMIS’ convergent validity in pediatric cancer patients. Hinds et al also found evidence of responsiveness over time for all PROMIS Pediatric measures except upper extremity function . Hinds et al did not include the PROMIS Pediatric measure of psychological stress that is included in this study …”

Section: Introductionmentioning

confidence: 83%

“…Development of the PROMIS Pediatric measurement system used a broad range of patient populations that included children with cancer. Recently, Hinds et al examined the responsiveness of eight PROMIS Pediatric measures in a single‐site cohort of 96 pediatric oncology patients between 13 and 18 years of age . They observed that the PROMIS Pediatric measures of depressive symptoms, fatigue, pain interference, and mobility correlated with similar items from the Symptom Distress Scale, providing support for PROMIS’ convergent validity in pediatric cancer patients.…”

Section: Introductionmentioning

confidence: 99%

“…It is critical that we continue to build a strong body of evidence regarding the validity of the PROMIS Pediatric measures for children and adolescents with cancer to support its use in clinical trials and healthcare delivery settings. Therefore, the goal of this study is to evaluate the construct validity of the PROMIS Pediatric measures in a much larger sample than previous studies of children and adolescents undergoing active cancer treatment . Additionally, we included children from a broad age range (ages 7‐18 years) who were more diverse in respect of demographic characteristics, geographic location, cancer type, and treatment modality.…”

Section: Introductionmentioning

confidence: 99%

“…12,13 Additionally, PROMIS is a flexible measurement system allowing investigators and clinicians to select HRQOL domains that are most relevant for their specific patient population or research question. In order to control questionnaire length, investigators can select an off-the-shelf short form in various lengths (e.g., 4-item 14 Hinds et al did not include the PROMIS Pediatric measure of psychological stress that is included in this study. 15 It is critical that we continue to build a strong body of evidence regarding the validity of the PROMIS Pediatric measures for children and adolescents with cancer to support its use in clinical trials and healthcare delivery settings.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment

Reeve

McFatrich

Mack

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Background The Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric measures were designed to assess symptoms and functioning in children and adolescents. The study goal was to evaluate the validity and responsiveness of the PROMIS Pediatric measures in a diverse cohort of children with cancer. Methods Children (7‐18 years) from nine pediatric oncology hospitals completed surveys at 72 hours preceding treatment initiation (T1) and at follow‐up (T2) approximately 7 to 17 days later for chemotherapy, and 4+ weeks later for radiation. Children completed PROMIS Pediatric measures (Mobility, Pain Interference, Fatigue, Depressive Symptoms, Anxiety, Psychological Stress), Memorial Symptom Assessment Scale (MSAS), and global impressions of change (GIC) questions on their symptoms and functioning at T2 reflecting on T1. Parents completed the Lansky Play‐Performance Status (PPS) scale and medication list for their child. Results The children (n = 482) were average age 12.9 years, 46% female, 60% Caucasian, and had diverse cancers and treatments. There were moderate to strong correlations between PROMIS Pediatric and MSAS, supporting convergent validity. In support for known‐groups validity, the PROMIS Pediatric average scores were statistically different (P < 0.05) for most domains by PPS and if the child was on a medication (or not) for controlling a symptom. The PROMIS Pediatric measures were responsive over time in association with the GIC. Conclusions In a large, diverse sample of children and adolescents with cancer, there was strong evidence for the construct validity and responsiveness of the PROMIS Pediatric measures. This evidence supports PROMIS Pediatric measure use in pediatric oncology trials.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Introductionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment

Reeve

McFatrich

Mack

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Agreement Between Child Self-report and Caregiver-Proxy Report for Symptoms and Functioning of Children Undergoing Cancer Treatment

et al. 2020

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Adult patients are considered the best reporters of their own health-related quality of life (HRQOL). Self-report in pediatrics has been challenged by a limited array of valid measures. Caregiver report is therefore often used as a proxy for child report.OBJECTIVES To examine the degree of alignment between child and caregiver proxy report for Patient-Reported Outcomes Measurement Information System (PROMIS) HRQOL domains among children with cancer and to identify factors associated with better child and caregiver-proxy congruence. DESIGN, SETTING, AND PARTICIPANTSIn this multicenter cohort study, children with a first cancer diagnosis and their caregivers completed surveys at 2 time points: within 72 hours preceding treatment initiation (T1) and during follow-up (T2), when symptom burden was expected to be higher (eg, 7-17 days later for chemotherapy). Data were collected from October 26, 2016, to October 5, 2018, at 9 pediatric oncology hospitals. Five hundred eighty children (aged 7-18 years) and their caregivers were approached; 482 child-caregiver dyads completed surveys at T1 (response rate 83%), and 403 completed surveys at T2 (84% of T1 participants). Data were analyzed from July 1, 2019, to April 22, 2020.EXPOSURES Participants received up-front cancer treatment, including chemotherapy and radiotherapy. MAIN OUTCOMES AND MEASURESCongruence between child self-report and caregiver-proxy report of PROMIS pediatric domains of mobility (physical functioning), pain interference, fatigue, depressive symptoms, anxiety, and psychological stress. RESULTSOf the 482 dyads included in the analysis, 262 children (54%) were male (mean [SD] age, 12.9 [3.4] years), 80 (17%) were Black, and 71 (15%) were Hispanic. Intraclass correlations between child self-report and caregiver proxy report showed moderate agreement for mobility (0.57 [95% CI, 0.50-0.63]) and poor agreement for symptoms (range, 0.32 [95% CI, 0.24-0.41] for fatigue to 0.42 [95% CI, 0.34-0.50] for psychological stress). Children reported lower symptom burden and higher mobility than caregivers reported. In a multivariable model adjusted for child and parent sociodemographic factors and the caregiver's own self-reported HRQOL, caregivers reported the child's mobility score 6.00 points worse than the child's self-report at T2 (95% CI, −7.45 to −4.51), exceeding the PROMIS minimally important difference of 3 points. Caregivers overestimated the child's self-reported symptom levels, ranging from 5.79 (95% CI, 3.99-7.60) points for psychological stress to 13.69 (95% CI,) points for fatigue. The caregiver's own self-reported HRQOL was associated with the magnitude of difference between child and caregiver scores for all domains except mobility; for example, for fatigue, the magnitude of difference between child and caregiver-proxy scores increased by 0.21 (95% CI, 0.13-0.30) points for each 1-point increase in the caregiver's own fatigue score.CONCLUSIONS AND RELEVANCE This study found that caregivers consistently overestimated symptoms and underestimat...

show abstract

Health‐related quality of life in adult and pediatric survivors

Mitchell

Wiener

Hoag

et al. 2021

Blood and Marrow Transplantation Long Term Management

View full text Add to dashboard Cite

PROMIS pediatric measures validated in a longitudinal study design in pediatric oncology

Cited by 56 publications

References 48 publications

Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment

Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment

Agreement Between Child Self-report and Caregiver-Proxy Report for Symptoms and Functioning of Children Undergoing Cancer Treatment

Health‐related quality of life in adult and pediatric survivors

Contact Info

Product

Resources

About